Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 842

1.

Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.

Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H.

Gynecol Oncol. 2009 Aug;114(2):253-9. doi: 10.1016/j.ygyno.2009.04.024. Epub 2009 May 14.

PMID:
19446316
2.

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA.

Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009. Epub 2008 Nov 28.

PMID:
19041126
3.

Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.

Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS.

Gynecol Oncol. 2007 Aug;106(2):381-7. Epub 2007 May 16.

PMID:
17509673
4.

Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.

Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D.

Cancer. 2009 Jun 1;115(11):2453-63. doi: 10.1002/cncr.24282.

5.

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):276-81. Epub 2007 Dec 11.

PMID:
18063020
6.

The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.

Kumpulainen S, Sankila R, Leminen A, Kuoppala T, Komulainen M, Puistola U, Hurme S, Hiekkanen H, Mäkinen J, Grénman S.

Gynecol Oncol. 2009 Nov;115(2):199-203. doi: 10.1016/j.ygyno.2009.07.011. Epub 2009 Aug 19.

PMID:
19695688
7.

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.

Gynecol Oncol. 2006 Aug;102(2):285-91. Epub 2006 Mar 3.

PMID:
16516283
8.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
9.

Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA.

Gynecol Oncol. 2005 May;97(2):436-41.

PMID:
15863142
10.

Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.

d'Amato TA, Pettiford BL, Schuchert MJ, Parker R, Ricketts WA, Luketich JD, Landreneau RJ.

Ann Surg Oncol. 2009 Oct;16(10):2848-55. doi: 10.1245/s10434-009-0608-0. Epub 2009 Jul 16.

PMID:
19609620
11.

Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.

Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS.

Gynecol Oncol. 2005 Apr;97(1):110-7.

PMID:
15790446
12.

The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.

Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Huh WK, Straughn JM Jr.

Gynecol Oncol. 2009 Aug;114(2):242-5. doi: 10.1016/j.ygyno.2009.04.019. Epub 2009 May 17.

PMID:
19447480
13.

Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.

Leiser AL, Chi DS, Ishill NM, Tew WP.

Gynecol Oncol. 2007 Jun;105(3):657-61. Epub 2007 Mar 28.

PMID:
17395252
14.

Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential.

Barakat RR, Benjamin I, Lewis JL Jr, Saigo PE, Curtin JP, Hoskins WJ.

Gynecol Oncol. 1995 Dec;59(3):390-3.

PMID:
8522261
15.

Advances in the management of epithelial ovarian cancer.

Berkenblit A, Cannistra SA.

J Reprod Med. 2005 Jun;50(6):426-38. Review.

PMID:
16050567
16.

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.

Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A.

Crit Rev Oncol Hematol. 2009 Sep;71(3):233-41. doi: 10.1016/j.critrevonc.2008.12.010. Epub 2009 Jan 28.

PMID:
19179095
17.

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI.

Clin Cancer Res. 2005 Mar 15;11(6):2149-55.

18.

Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.

Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E.

Gynecol Oncol. 2008 Jan;108(1):136-40. Epub 2007 Oct 23.

PMID:
17936342
19.

Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.

Aletti GD, Podratz KC, Cliby WA, Gostout BS.

Gynecol Oncol. 2009 Jan;112(1):22-7. doi: 10.1016/j.ygyno.2008.09.010. Epub 2008 Oct 23.

PMID:
18947860
20.

The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.

Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb.

Items per page

Supplemental Content

Write to the Help Desk